Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival

Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival

Abstract Background The effect of first‐line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED‐SCLC). Therefore, we evaluated the relationship between progression‐free survival (PFS), post‐progre...

Full description

Bibliographic Details
Main Authors: Ken Masubuchi, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Hiroyuki Minemura, Yoshiaki Nagai, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Ayako Shiono, Hiroki Takechi, Jun Shiihara, Kyoichi Kaira, Kenya Kanazawa, Hirokazu Taniguchi, Takayuki Kaburagi, Hiroshi Kagamu, Koichi Minato
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Thoracic Cancer
Subjects:
atezolizumab
carboplatin
etoposide
overall survival
post‐progression survival
Online Access:https://doi.org/10.1111/1759-7714.14621

Internet

https://doi.org/10.1111/1759-7714.14621

Similar Items